Results 141 to 150 of about 1,582,904 (250)
Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines +8 more
wiley +1 more source
Pest Management Science, Volume 82, Issue 10, Page 9437-9443, October 2026.Target‐site based imidazolinone resistance in brome grass was found to be conferred by a mutation at position 574 in the ALS gene and to severely impact the efficacy of the herbicide Intervix®, a co‐formulation of imazamox and imazapyr. Abstract BACKGROUND Brome grass (Bromus diandrus) is a prevalent weed in southern Australian cropping regions which ...
Roberto Busi +5 more
wiley +1 more source
Pest Management Science, Volume 82, Issue 10, Page 10134-10146, October 2026.Foramsulfuron remains effective on Pro‐197 Poa annua, but co‐formulation with thiencarbazone reduces efficacy due to limited activity and antagonism. Therefore, foramsulfuron + thiencarbazone should be used in fields without ALS‐resistant weeds to ensure effective in‐crop control.
Vijaya Bhaskar Alwarnaidu Vijayarajan +6 more
wiley +1 more source
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda +4 more
wiley +1 more source
Deconstructing the Master Switch: Advances in Direct NLRP3 Inhibition. [PDF]
Pharmaceuticals (Basel)Xu Y, Murphy S.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9403-9411, October 2026.ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii +5 more
wiley +1 more source